Article Text

other Versions

Download PDFPDF
‘No-Barriers’ tobacco product? Selling smokeless tobacco to women, people of colour and the LGBTQ+ community in the USA
  1. Yogi Hale Hendlin1,2,
  2. Sarah Small1,
  3. Pamela M Ling1,3
  1. 1Center for Tobacco Control Research and Education, University of California San Francisco, San Francisco, California, USA
  2. 2Dynamics of Inclusive Prosperity Initiative, Erasmus University Rotterdam, Rotterdam, South Holland, Netherlands
  3. 3Department of Medicine, Division of General Internal Medicine, University of California San Francisco, San Francisco, California, USA
  1. Correspondence to Dr Pamela M Ling, Department of Medicine, Center for Tobacco Control Research and Education, University of California San Francisco, San Francisco, CA 94143, USA; Pamela.Ling{at}ucsf.edu

Abstract

Background In both Sweden and the USA, smokeless tobacco (ST) is legal and used predominantly by men. Starting in the 1970s, US tobacco companies attempted to expand the ST market to women, African Americans, Hispanic Americans and lesbian, gay, bisexual, transgender, queer and other sexual orientation (LGBTQ+) people.

Design We analysed industry documents from the Truth Tobacco Industry Documents Library triangulating findings with recent ST advertising and publicly available literature.

Findings We found tobacco companies used design innovations such as pouched moist snuff, snus and dissolvable products to expand the market. In addition, diverse advertising campaigns targeted women, people of colour (Hispanic, African American) and LGBTQ+ communities with identity-targeted messages emphasising novelty, convenience, cleanliness and use in smoke-free environments. However, stereotypes of ST users as rural white males endured, perpetuated by continued marketing aimed at this customer base, which created cognitive dissonance and stymied marketer’s hopes that pouch products would ‘democratize’ ST.

Conclusion These failed campaigns suggest novel products such as nicotine pouch products may provide a ‘clean slate’ to similarly target women and other low-ST-using groups. Based on this history, the risk of new tobacco and nicotine products to increase health disparities should be closely monitored.

  • advertising and promotion
  • tobacco industry documents
  • priority/special populations
  • non-cigarette tobacco products

Data availability statement

Data are available in a public, open access repository. All data for this study are openly and publicly available tobacco industry documents freely and immediately available at the Truth Tobacco Documents Library (https://www.industrydocuments.ucsf.edu/tobacco).Images in Figures are openly and publicly available from the Trinkets and Trash archive (https://www.trinketsandtrash.org/) or the Stanford Research into the Impact of Tobacco Advertising archive (https://tobacco.stanford.edu/).

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available in a public, open access repository. All data for this study are openly and publicly available tobacco industry documents freely and immediately available at the Truth Tobacco Documents Library (https://www.industrydocuments.ucsf.edu/tobacco).Images in Figures are openly and publicly available from the Trinkets and Trash archive (https://www.trinketsandtrash.org/) or the Stanford Research into the Impact of Tobacco Advertising archive (https://tobacco.stanford.edu/).

View Full Text

Footnotes

  • Contributors YH conceived the study and SS led the data acquisition. YH and SS drafted the manuscript. PL obtained funding and oversaw data collection. All authors contributed to the analysis and interpretation of the data and in revising the manuscript critically for important intellectual content.

  • Funding This work was supported by the National Cancer Institute at the National Institutes of Health (grant numbers R01 CA141661 and T32 CA113710).

  • Disclaimer The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.